Trial · NCT07562022
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | Up to approximately 3 years | Treatment-emergent adverse events/serious adverse events/adverse events of special interest |
| Primary | Progression free survival (PFS) | Up to approximately 3 years | Defined as the time from the date of randomization to the date of first documentation of progression disease (PD) or the date of death from any cause, whichever occurs first. |
| Secondary | Percentage of Participants Achieving Best Overall Response (BOR) | Up to approximately 3 years | BOR is defined as Complete Response (CR) or Partial Response (PR), determined by Lugano criteria |
| Secondary | Percentage of Participants Achieving CR | Up to approximately 3 years | Percentage of participants who achieve a CR determined per Lugano criteria. |
| Secondary | Overall Survival (OS) | Up to approximately 3 years | Overall survival is defined as the duration from the date of randomization to the date of the participant's death. |
| Secondary | Duration of Response (DOR) | Up to approximately 3 years | DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first. |
| Secondary | Time to Response (TTR) | Up to approximately 3 years | Time to response is defined for participants achieving a CR/PR as the time from starting therapy to first a CR/PR. |
| Secondary | Event-Free Survival (EFS) | Up to approximately 3 years | EFS is defined as the duration from randomization to disease progression determined by Lugano criteria as assessed by the investigator, initiation of any non-protocol-specified new anti-lymphoma therapy for any reason, or death (whichever occurs first). |
| Secondary | Duration of Complete Response (DOCR) | Up to approximately 3 years | DOCR is defined as the time from the first occurrence of CR to disease progression or death, whichever occurs first. |
| Secondary | Time to Complete Response (TTCR) | Up to approximately 3 years | Time to complete response is defined for participants achieving a CR as the time from starting therapy to first a CR. |
| Secondary | Blood Concentrations of SCTB35 | Up to approximately 1 years | The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative) |
| Secondary | Anti-drug Antibodies of SCTB35 | Up to approximately 3 years | Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07562022/registered